Welcome to our dedicated page for Sarepta Therapeutics SEC filings (Ticker: SRPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sarepta Therapeutics, Inc.'s SEC filings document an operating biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under SRPT. Form 8-K reports furnish quarterly and annual financial results, product revenue disclosures for ELEVIDYS and PMO therapies, and clinical or regulatory updates for Duchenne muscular dystrophy treatments and siRNA pipeline programs.
Other filings cover proxy governance, executive compensation, equity-award plans and leadership-transition disclosures. Material-event reports also describe capital-structure actions, including exchange agreements for convertible senior notes, issuance of new convertible notes, common stock consideration and related indenture terms.
Sarepta Therapeutics (SRPT) Form 3 records newly appointed CFO Ryan Ho-Yan Wong’s initial beneficial ownership as of 16 Jul 2025. He directly holds 17,655 common shares. The filing also lists 11 stock-option grants covering 31,031 shares with exercise prices between $67.78 and $155.99 and expirations from 2031-2035; each grant vests 25 % at the first anniversary and then monthly. No shares were bought or sold—this is a baseline disclosure required under Section 16(a). The document contains no operating, financial, or strategic updates and is unlikely to affect the investment thesis for SRPT.
D. E. Shaw & Co., L.P. and founder David E. Shaw filed Amendment No. 1 to Schedule 13G disclosing a passive 5.1 % holding (5,059,912 shares) in Sarepta Therapeutics (SRPT) as of 18 Jul 2025. The stake is spread across three internal vehicles: D. E. Shaw Valence Portfolios (2.78 m shares), D. E. Shaw Oculus Portfolios (1.39 m) and accounts managed by D. E. Shaw Investment Management (0.89 m).
The reporting persons have shared voting power over 5,000,212 shares and shared dispositive power over the full 5,059,912 shares; they possess no sole voting or dispositive authority. The filing is made under Rule 13d-1(b) as an investment adviser and states the shares were not acquired to influence control of the issuer.
This amendment corrects the original 13G by attaching the Joint Filing Agreement dated 25 Jul 2025; no changes to ownership levels or intent are reported.